COMMUNIQUÉS West-GlobeNewswire

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial
20/02/2026
Regulatory clearance enables start of clinical testing and marks transition to clinical-stage company On track for initial clinical data to emerge from mid-2026 Oslo, Norway, 20 February 2026 – Zelluna (OSE: ZLNA), a [...]
Syncx Accelerates the Future of Locums Staffing with Major Platform Enhancements and Rapid AI Expansion
20/02/2026
ATLANTA, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Syncx today announced a major wave of platform enhancements and AI-driven capabilities that are available starting February 23rd and rolling out through March. These [...]
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
20/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution
20/02/2026
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
Lifeward Announces Reverse Share Split
20/02/2026
Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: [...]
Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
20/02/2026
– Administration of PEDMARK ® Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for Adults with Head & Neck Cancers (HNC) – – Early Signals of Hearing Preservation [...]
BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference
20/02/2026
POMPANO BEACH, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue derived [...]
VitalHub Announces Q4 2025 Conference Call Date
20/02/2026
TORONTO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX:VHI) (OTCQX:VHIBF) (the "Company" or "VitalHub") is pleased to announce that it will release financial results for the fourth quarter 2025 ended December 31 [...]
Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
20/02/2026
ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement [...]
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
20/02/2026
DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Biocomposites to launch SYNICEM™ bone cement in UK to ease supply crisis
20/02/2026
Biocomposites responds to NHS supply crisis by bringing forward launch of its SYNICEM™ bone cement products in the UK Over 500,000 SYNICEM™ bone cement packs are already used by surgeons globally every year to help [...]
YWECARE Expands Across Australia as Demand Grows for Transparent and Accountable NDIS Providers
20/02/2026
YWECARE Emerges as One of Australia’s Fast-Growing NDIS Providers Sydney, NSW, Feb. 20, 2026 (GLOBE NEWSWIRE) -- In an industry often under supervision for inconsistency and compliance failures, an NDIS PROVIDER is [...]
PL BioScience Signs Exclusive Japanese Distribution Agreement with Summit Pharmaceuticals International
20/02/2026
Summit Pharmaceuticals International Corp. to serve as exclusive distributor for cell culture supplements in Japanese Market. The agreement marks PL BioScience’s first exclusive distribution partnership in Japan. Cell [...]
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
20/02/2026
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1 -mutated populations, respectively, versus standard-of-care [...]
RAMSAY SANTE : New step for Ramsay Santé in connection with Ramsay Health Care's proposal to distribute its shareholding in Ramsay Santé to its shareholders
20/02/2026
PRESS RELEASE Paris, 20 February 2026 New step for Ramsay Santé in connection with Ramsay Health Care's proposal to distribute its shareholding in Ramsay Santé to its shareholders Ramsay Générale de Santé (“ Ramsay [...]
Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin
20/02/2026
ALK’s (ALKB:DC / Nasdaq Copenhagen: ALK B) full-year results came in at the top end of the latest outlook, supported by solid performance in Q4 and continued commercial momentum. ALK expects sustained high organic [...]
O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
20/02/2026
Data from the first in human study on O3R-5671’s potent TNFα inhibition Studies in ulcerative colitis and psoriasis to initiate in H2 2026 Leuven, Belgium. February 20, 2025 . Onco3R Therapeutics, a clinical-stage [...]
RAMSAY SANTE : Nouvelle étape pour Ramsay Santé, dans le cadre du projet de distribution par Ramsay Health Care à ses actionnaires de sa participation dans Ramsay Santé
20/02/2026
COMMUNIQUÉ DE PRESSE Paris, le 20 février 2026 Nouvelle étape pour Ramsay Santé, dans le cadre du projet de distribution par Ramsay Health Care à ses actionnaires de sa participation dans Ramsay Santé Ramsay Générale de [...]
Henriette Mersebach to step down as ALK’s head of R&D
20/02/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Henriette Mersebach will step down as Executive Vice President, Research and Development, and as a member of the Board of Management, effective 23 February [...]

Pages